Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

GlobeNewswire February 26, 2021

PharmaTher Announces Sale of Psilocybin Program

GlobeNewswire February 17, 2021

Revive Therapeutics Acquires Unique Psilocybin Assets

GlobeNewswire February 17, 2021

Revive Therapeutics (CSE:RVV) announces closing of $23 M short form prospectus offering

Isabella Zavarise February 12, 2021

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

GlobeNewswire February 12, 2021

These are Some of the Top Cannabis Companies Generating Substantial Interest

Livemoney February 11, 2021

Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program

GlobeNewswire February 11, 2021

Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

GlobeNewswire February 9, 2021

Revive Therapeutics Files Business Acquisition Report

GlobeNewswire February 8, 2021

Naturally-Derived Compounds Have Anti-Cancer Properties that Could Help Millions

Livemoney January 25, 2021

Revive Therapeutics Included in First Psychedelic Exchange Traded Fund

GlobeNewswire January 22, 2021

Revive Therapeutics (CSE:RVV) among 17 companies listed in first psychedelics ETF

Simon Druker  January 22, 2021

IIROC Trade Resumption - RVV

Canada NewsWire January 21, 2021

Revive Therapeutics Announces Upsize to Previously Announced Bought Deal Offering

Canada NewsWire January 21, 2021

IIROC Trading Halt - RVV

Canada NewsWire January 21, 2021

Revive Therapeutics Announces $10 Million Bought Deal Offering of Units

Canada NewsWire January 20, 2021

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

GlobeNewswire January 14, 2021

Psilocybin is Being Studied to Help Treat Autism Spectrum Disorder

Livemoney January 13, 2021

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

GlobeNewswire December 31, 2020

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

GlobeNewswire December 23, 2020